A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition
NCT ID: NCT07086664
Last Updated: 2026-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
7 participants
INTERVENTIONAL
2025-08-05
2026-01-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study medicine PF-07258669 is being developed for the treatment of unintended weight loss in older adults. People with this condition have decreased appetite and food intake, which is an important reason for poor nutrition and health results in people with unintended weight loss.
This is approximately a 26-week-long study with 9 visits to the study doctor and 4 telehealth visits (ie. visits by phone call). The study will include
* Screening period for up to 4 weeks
* Pre-treatment period of 2 weeks
* Treatment period of 16 weeks : study drug (PF-07258669 or matching placebo)
* Follow-up period of 4 weeks The study requires answering questionnaires and use of digital devices at home to measure blood pressure and physical activity. The study team will monitor how each participant is doing during the study
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin
NCT01262690
A Study to Understand How the Body Processes [14C]PF-07104091 in Healthy Participants
NCT07127770
A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers
NCT00736528
A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy Adults
NCT06706869
A Study To Evaluate the Safety, Tolerability, And Pharmacokinetics Of PF-06266047 In Healthy Adult Subjects
NCT02539550
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo
Oral tablet
PF-07258669
PF-07258669
Oral tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Oral tablet
PF-07258669
Oral tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
60 Years
89 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Accel Research Sites - Birmingham Clinical Research Unit
Birmingham, Alabama, United States
JEM Research Institute
Atlantis, Florida, United States
Bradenton Research Center, Inc.
Bradenton, Florida, United States
McKnight Brain Institute
Gainesville, Florida, United States
De La Cruz Research Center, LLC
Miami, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
Headlands Research Orlando
Orlando, Florida, United States
Shields MRI Brockton
Brockton, Massachusetts, United States
Headlands Eastern MA LLC
Plymouth, Massachusetts, United States
AA Medical Research Center
Flint, Michigan, United States
Clinical Research Professionals
Chesterfield, Missouri, United States
Javara - Nevada Health Centers - Carson City
Carson City, Nevada, United States
Circuit Clinical
Secaucus, New Jersey, United States
Circuit Clinical /North Hudson Community Action Corporation
West New York, New Jersey, United States
OCT Research ULC
Kelowna, British Columbia, Canada
Alpha Recherche Clinique - Lévis
Lévis, Quebec, Canada
Diex Recherche Trois-Rivieres
Trois-Rivières, Quebec, Canada
Diex Recherche Inc. Division Victoriaville
Victoriaville, Quebec, Canada
Centre de Recherche Saint-Louis inc.
Québec, , Canada
ALPHA Recherche Clinique
Québec, , Canada
Shonan Fujisawa Tokushukai Hospital
Fujisawa, Kanagawa, Japan
Yao Tokushukai General Hospital
Yao Shi, Osaka, Japan
Juntendo Tokyo Koto Geriatric Medical Center
Koto-ku, Tokyo, Japan
Yamagata Tokushukai Hospital
Yamagata, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-520763-41-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
C4541011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.